◈ Nootpedia
Compact view
Research pass: thorough Pharmaceutical · Oral SKIP-PERMANENT HIGH

Phenibut

Extended Research
◈ Extended Research ◈

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

▸ Our verdict SKIP-PERMANENT HIGH

Phenibut produces severe physiological dependence within 1-3 weeks of regular use, withdrawal that mirrors benzodiazepine/alcohol withdrawal severity (autonomic crisis, delirium, seizures, ICU-level care), and a 2024 systematic review documenting 44% of withdrawal cases requiring ICU, 24% intubated, 8% with seizures. Recreational doses (1-3 g) used in biohacker contexts are 5-15× the Russian therapeutic dose (250-500 mg). The dependence pharmacology is fundamental to the molecule — there is no safe low-dose intermittent protocol that survives contact with weekly use. For an anxiolytic effect, Selank (zero-dependence) and L-theanine + taurine (free-tier) cover the use case without the abyss. Verdict applies to ALL archetypes — no compelling clinical use case where benefit exceeds dependence risk for a non-prescribed user. Would change ONLY if a non-tolerizing analogue of phenibut were discovered or if molecular-tolerance data fundamentally re-wrote the dependence model — neither is plausible given 60+ years of clinical data. Dylan-specific reinforcement: at 20 with high cognitive workload + MMA training + zero substance baseline, introducing a known dependence trap is a strict downside trade.

Research pass: thorough
▸ Decision matrix by user profile Per-archetype
  • Dylan20-30, brain-priority, high cognitive workload (Dylan-archetype)
    SKIP-PERMANENT

    HIGH confidence. At 20 with zero substance baseline and high cognitive demand, introducing a drug that down-regulates GABA-B + α2δ tone produces predictable rebound anxiety + cognitive blunting on missed doses, undermining the "sustained 6-12 hr cognitive output" goal. Dependence onset within 1-3 weeks would force either continuous use (defeats the purpose) or a managed withdrawal that costs weeks of cognitive function. Selank covers anxiolysis without dependence; L-theanine + taurine cover acute calm without dependence. No remaining use case.

  • 30-50, executive maintenance
    SKIP-PERMANENT

    Same dependence calculus; additional concern that polypharmacy with statins, antihypertensives, or SSRIs raises pharmacodynamic interaction surface. Better Rx anxiolytics exist (SSRIs, buspirone, hydroxyzine, gabapentin under controlled setting).

  • 50+, mild cognitive decline
    SKIP-PERMANENT

    GABA-B agonism in older brains worsens memory + falls + cognitive function. Withdrawal in elderly is more dangerous (delirium superimposed on baseline cognitive vulnerability). No upside.

  • Anxiety-prone
    SKIP-PERMANENT

    Counterintuitively, this is the highest-risk archetype — the immediate anxiolytic effect is most reinforcing precisely where dependence forms fastest. Use SSRI/SNRI baseline + Selank/buspirone/hydroxyzine PRN; never phenibut.

  • High athletic load, tested status
    SKIP-PERMANENT

    Sedation interferes with training; rebound anxiety + autonomic instability disrupt sleep + recovery; WADA status currently uncontrolled but unsafe regardless.

  • Sleep-disordered
    SKIP-PERMANENT

    Initial sleep benefit yields fast tolerance; rebound insomnia on missed doses worse than starting baseline. Daridorexant or trazodone are dramatically better Rx options; melatonin, glycine, magnesium, apigenin cover non-Rx tier.

  • Recovery-focused (post-injury, post-illness)
    SKIP-PERMANENT

    No role.

  • Strength/anabolic-focused
    SKIP-PERMANENT

    Sedation undermines training; no anabolic benefit; no rationale. No archetype where verdict is anything other than SKIP-PERMANENT. This is one of the rare compounds in this wiki where the across-archetype verdict is unanimous — comparable to retatrutide-for-athletes (different mismatch reason) or SARMs-at-20 (different mismatch reason).

▸ Subjective experience (deep)

At low doses (250-500 mg, Russian therapeutic):

  • Calm, mild anxiolysis — described as "background anxiety quieting"
  • Mild stimulation / sociability (likely PEA-antagonism + weak dopaminergic action)
  • Sleep onset improved without next-day grogginess in some users
  • Onset slow (1.5-3 hr) — frequently mistaken for inactivity, leading to re-dosing and accidental escalation
  • Duration 10-16 hr

At recreational doses (1-3 g):

  • "Alcohol without alcohol" — euphoric anxiolytic, social disinhibition, mild euphoria, music enhancement
  • Comparable to a moderate dose of alcohol or a low dose of GHB in subjective profile
  • Cross-tolerance with benzodiazepines, alcohol, GHB, baclofen, gabapentinoids
  • Strong reinforcement profile — users describe "wanting more" within days of first use

Tolerance trajectory:

  • Days 1-3: Full subjective effect at chosen dose
  • Day 4-7: Noticeable tolerance — same dose feels weaker
  • Week 2-3: Dose escalation common (1 g → 2 g → 3 g+)
  • Week 3-4: Physical dependence often established at daily use
  • Withdrawal upon stopping: Onset 2-3 hours after last dose (matches t½)

Withdrawal experience (the central reason for SKIP-PERMANENT):

  • Hours 2-12: Anxiety surge, restlessness, insomnia, tremor, sweating, tachycardia
  • Hours 12-72: Peak — autonomic crisis (BP swings, tachycardia, profuse sweating, vomiting, diarrhea), delirium, hallucinations (visual and auditory), psychosis-like presentations, agitation, suicidal ideation, seizures
  • Days 3-14: Protracted insomnia, rebound anxiety worse than baseline, depression, anhedonia, muscle pain, "feeling fundamentally broken"
  • Weeks 2-8: Gradual normalization; some users report PAWS (post-acute withdrawal syndrome) lasting months — anxiety, sleep disruption, anhedonia
  • Severity is comparable to moderate-to-severe benzodiazepine withdrawal or alcohol withdrawal with delirium tremens — i.e., a withdrawal syndrome that can kill if managed badly. Inpatient management with benzodiazepines/barbiturates ± baclofen taper is standard.
▸ Tolerance + cycling deep dive
  • Tolerance buildup: extremely fast. Within days at daily dosing. Within 2-3 weeks at twice-weekly dosing. The pharmacology of GABA-B agonism + α2δ binding produces both pharmacodynamic tolerance (receptor down-regulation) and rapid functional tolerance.
  • Recommended cycle: None. No cycling protocol survives contact with the dependence pharmacology in real-world use. "Once weekly" intentions reliably erode toward more frequent use because of withdrawal-driven anxiety rebound.
  • Reset protocol: A medically supervised inpatient taper is the only reliable "reset" once dependence is established. Self-directed tapers are routinely abandoned mid-course because of withdrawal severity, leading to relapse. Outpatient taper protocols using baclofen substitution (titrated baclofen taper covering 4-12 weeks) have been published but require physician oversight.
  • Cross-tolerance: With baclofen, GHB/GBL, gabapentin, pregabalin, alcohol, and benzodiazepines (incomplete but clinically meaningful). Withdrawal can be managed with any of these as substitution agents — a clinical fact that has nothing to do with safe recreational use.
▸ Stacking deep dive

Synergistic with (recreational — DO NOT USE)

  • Alcohol, benzodiazepines, GHB, opioids: multiplicative respiratory depression, multiplicative dependence. Lethal combinations. Documented in death cases.
  • Other gabapentinoids (gabapentin, pregabalin): additive α2δ binding; users report potentiation but also accelerated dependence development. Listed under "DO NOT" not "synergistic."

Avoid stacking with

  • Anything in the GABAergic/depressant family — alcohol, benzodiazepines, Z-drugs, GHB, baclofen, gabapentin, pregabalin, opioids, ketamine
  • MAOIs (selegiline, moclobemide): theoretical concern via β-PEA mechanism — under-characterized
  • Other Russian compounds with overlapping anxiolytic intent — picamilon, selank — redundant target, no synergy benefit, replaces a safe tool with the dangerous one

Neutral / safe co-administration

  • Not relevant — verdict is don't take it at all. The "neutral" category is moot.
▸ Drug interactions deep dive
  • No significant CYP induction/inhibition — phenibut is largely excreted unchanged in urine (~63%), minimal hepatic metabolism. Drug-drug interactions are pharmacodynamic (additive CNS depression with depressants) rather than pharmacokinetic.
  • Renal function: Dose adjustment needed in renal impairment (relevant if ever Rx-prescribed; irrelevant in biohacker context because the verdict is don't use it).
  • Contraceptive interactions: None known.
  • Polysubstance overdose risk: Multiplicative with alcohol, benzodiazepines, opioids, other GABAergic depressants. This is the dominant interaction concern in the recreational-use population.
▸ Pharmacogenomics
  • No actionable PGx for phenibut response or dependence risk as of 2026. This is a gap, not a reassurance — phenibut has not received the PGx attention given to gabapentin or baclofen, but the dependence pharmacology is unlikely to be PGx-rescuable. Do not interpret absence of PGx data as "low risk for some genotype."
  • GABA-B receptor (GABBR1, GABBR2) variants: Implicated in benzodiazepine response and alcohol use disorder; presumed to affect phenibut similarly but no direct studies.
  • CACNA2D1 (α2δ-1 subunit): Variants implicated in gabapentinoid response; presumed relevance but undetermined.
  • Practical takeaway for Dylan: Even if 23andMe shows favorable variants on related genes (June 2026 results window), the verdict does not change. Genotype-mediated risk reduction is speculative; the dependence pharmacology is universal.
▸ Sourcing deep dive
Path Vendor Cost Reliability Notes
Russian Rx pharmacy (in Russia/CIS) Local pharmacy, Rx required $5-15/box (20× 250 mg tabs) High Legal use case; not relevant for US biohacker context. RUPharma exports to gray-market US buyers.
Gray-market "research chem" / nootropic vendor (US) LiftMode, NewMind, Nootropics Depot (historical — ND discontinued), various Eastern European mail-order $20-50 / 100 g powder; $30-60 / 30 ct capsules Low-Medium — quality variable, dosing per-capsule frequently misstated (Polish 2024 study found up to 450% over label) FDA banned phenibut-as-supplement April 2019; warning letters to multiple vendors; major retailers (Amazon, GNC) removed. Smaller online vendors persist.
Gas-station / "smoke shop" supplement Various kratom-adjacent retailers $15-40 per bottle Very low — mislabeled, often combined with kratom or tianeptine ("gas station heroin" cluster) State bans accelerating — Alabama Schedule II since November 2021; Louisiana, Minnesota, Mississippi, Tennessee considering. Federal scheduling under intermittent CSPI/FDA pressure.
Direct Russian export RUPharma, CosmicNootropic, similar $25-50 per box Medium — actual phenibut, but US import may be seized; product is real. Same vendors Dylan uses for other Russian compounds. Sourcing solvability is not the question — the molecule itself is the problem.

Sourcing-difficulty rating: research-chem. The drug is obtainable but its retail status is increasingly hostile — FDA action 2019, accelerating state bans 2021-2026, no Western Rx access, dose-labeling unreliability in supplement market.

Key point: Sourcing is solvable. The verdict is shouldn't take it, not can't get it.

▸ Biomarkers to track (deep)

Not applicable — the verdict is not to take it. Biomarker monitoring is for use-case scenarios. Listed for completeness in case of forced clinical exposure (e.g., if someone enters care already dependent):

  • If exposure occurs (e.g., presenting in withdrawal):
    • Vital signs q1-2hr (HR, BP, temperature, RR, O2 sat) — autonomic crisis monitoring
    • Continuous cardiac telemetry during peak withdrawal (24-72 hr)
    • Electrolytes (Na, K, Mg, phosphate) — depletion common in autonomic crisis with vomiting/diarrhea
    • LFTs (ALT, AST) — transaminitis at chronic high doses
    • LC-MS toxicology (standard immunoassay does NOT detect phenibut; positive serum/urine confirms exposure)
    • CIWA-style adapted withdrawal score q4-6hr
    • Seizure precautions; EEG if concerning mental status
  • Post-discontinuation tracking:
    • Subjective anxiety + sleep VAS daily for 4-8 weeks (PAWS monitoring)
    • Repeat LFTs at 4 weeks if elevated at presentation
▸ Controversies / open debates Live debate
  1. "Therapeutic Russian use proves it's safe." False. At Russian Rx doses (250-500 mg, monitored, time-limited), phenibut has an acceptable benefit:risk for the indications listed. But Western recreational/biohacker use sits at 5-15× this dose, in unmonitored contexts, with no built-in stop date. The Russian clinical envelope and the Western biohacker envelope are different drugs in practice. Citing Russian Rx safety to defend US biohacker use is a category error.
  2. "Low-dose intermittent use is fine." False in practice. Tolerance + dependence have been documented at 2-3 g/day for 1 week (case literature). Twice-weekly recreational use shows tolerance emergence within 4-8 weeks. The pharmacology of GABA-B + α2δ neuroadaptation does not respect user dosing intentions. Every "I'll just use it on weekends" plan in r/Phenibut converges on either dependence or abandonment of the protocol. The honest answer is that there is no demonstrated safe-and-effective intermittent protocol for non-prescribed use.
  3. "Phenibut is safer than benzos." Partially false. Acute toxicity is lower than short-acting benzos (less respiratory depression at common doses), but withdrawal severity is comparable to benzos and tolerance builds faster. The "safer than benzos" framing — repeated by supplement marketers — is a marketing claim, not a clinical one.
  4. "Cross-tolerance with gabapentin makes it useful for gabapentin tolerance breaks." Discussed in case reports; represents harm-reduction for already-dependent gabapentinoid users, not a recommendation. Substituting one α2δ drug for another doesn't address dependence — it relocates it.
  5. "Phenibut helps social anxiety / autism-spectrum / ADHD comorbid anxiety better than SSRIs." Anecdotal pattern in user reports — there's a subset of users who describe profound subjective benefit that SSRIs don't replicate. Even if true at the individual level, the dependence pharmacology overrides this. The same population would be better served by Selank, hydroxyzine, low-dose buspirone, or formal GAD/SAD treatment — not phenibut.
  6. Where my prior verdict might be wrong: Hard to imagine a scenario. The dependence + withdrawal pharmacology has been replicated in Western, Russian, and Australian case literature for two decades. The 2024 systematic review and 2024 Gurley review both confirm the pattern. The strongest steel-man for phenibut would be a clinical context with strict prescription oversight + time-limited course + supervised taper — i.e., the Russian system. That's not a model that translates to US biohacker self-directed use.
▸ Verdict change log
  • 2026-05-05 — Initial verdict: SKIP-PERMANENT, HIGH confidence. Rationale: 60+ years of clinical pharmacology converging on a clear pattern — useful Rx anxiolytic at therapeutic doses with monitoring; predictably catastrophic in unmonitored biohacker dosing. 2024 systematic review (44% ICU, 24% intubation, 8% seizure) seals the case. No archetype where benefit > harm for non-prescribed users. What would change verdict: essentially nothing realistic. A novel non-tolerizing GABA-B agonist analog could change verdict on the analog (not on phenibut itself). Discovery that the dependence pharmacology is genotype-restricted to a small population could open targeted use, but no such evidence exists or is forthcoming.
▸ Open questions / gaps Open
  1. Why Western Rx markets never adopted phenibut despite Russian clinical track record. Likely answer: dependence + withdrawal severity unacceptable to FDA/EMA standards plus existing alternatives (gabapentin, pregabalin, baclofen, benzodiazepines, SSRIs) cover most use cases with better risk profiles. But a formal regulatory rationale would be useful for completeness.
  2. Federal US scheduling timeline. State-level scheduling is accelerating (Alabama 2021; multiple states pursuing 2024-2026). Federal Schedule IV or V is plausible by 2027-2028 if "gas station drug" pressure continues. Verdict doesn't change either way — already SKIP-PERMANENT — but sourcing surface narrows.
  3. PGx for dependence risk. Currently un-investigated. If a future genome-wide association study identified a dependence-resilient subpopulation, individual decisions could re-open — but this is speculative and not a near-term probability.
  4. Long-term cognitive effects post-recovery. PAWS (post-acute withdrawal syndrome) reports anecdotally suggest months-long cognitive dulling + anhedonia post-recovery; formal cognitive-recovery longitudinal data is lacking.
  5. Comparative withdrawal severity vs. baclofen. Both are GABA-B agonists; baclofen has its own withdrawal syndrome (also severe, sometimes fatal). Direct head-to-head data is thin. For Dylan and the wiki at large, this is moot — both are SKIP-PERMANENT outside specific Rx indications.
▸ Sources (full, with our context)
Back to compact view